Evidence map›Paper›PMID 26047625›Full record

ArticleEuropean journal of endocrinology2015

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.

Sebastian J C M M Neggers, Vyacheslav Pronin, Inga Balcere, Moon-Kyu Lee, Liudmila Rozhinskaya, Marcello D Bronstein, Mônica R Gadelha, Pascal Maisonobe, Caroline Sert, Aart Jan van der Lely and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Can acromegaly be controlled in all cases?Journal of neuroendocrinology · 2026
    Review
  8. Current controversies in acromegaly care.The Journal of clinical endocrinology and metabolism · 2026
    Review
  9. Article
  10. Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025
    Review
  11. Article
  12. Review
  13. Review
  14. Observational
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sebastian J C M M NeggersDepartment of EndocrinologyErasmus Medical Center, Rotterdam, NetherlandsDepartment of EndocrinologyI.M. Sechenov First Moscow State Medical University, Moscow, Russian FederationDepartment of EndocrinologyPauls Stradins Clinical University Hospital, Riga, LatviaDivision of Endocrinology and MetabolismSamsung Medical Center, Sungkyunkwan University, Seoul, Republic of KoreaDepartment of Neuroendocrinology and Bone DiseasesNational Endocrinology Research Centre, Moscow, Russian FederationNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, BrazilEndocrine SectionHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilIpsen Boulogne-BillancourtFrance s.neggers@erasmusmc.nl.
Vyacheslav ProninDepartment of EndocrinologyErasmus Medical Center, Rotterdam, NetherlandsDepartment of EndocrinologyI.M. Sechenov First Moscow State Medical University, Moscow, Russian FederationDepartment of EndocrinologyPauls Stradins Clinical University Hospital, Riga, LatviaDivision of Endocrinology and MetabolismSamsung Medical Center, Sungkyunkwan University, Seoul, Republic of KoreaDepartment of Neuroendocrinology and Bone DiseasesNational Endocrinology Research Centre, Moscow, Russian FederationNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, BrazilEndocrine SectionHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilIpsen Boulogne-BillancourtFrance.
Inga BalcereDepartment of EndocrinologyErasmus Medical Center, Rotterdam, NetherlandsDepartment of EndocrinologyI.M. Sechenov First Moscow State Medical University, Moscow, Russian FederationDepartment of EndocrinologyPauls Stradins Clinical University Hospital, Riga, LatviaDivision of Endocrinology and MetabolismSamsung Medical Center, Sungkyunkwan University, Seoul, Republic of KoreaDepartment of Neuroendocrinology and Bone DiseasesNational Endocrinology Research Centre, Moscow, Russian FederationNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, BrazilEndocrine SectionHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilIpsen Boulogne-BillancourtFrance.
Moon-Kyu LeeDepartment of EndocrinologyErasmus Medical Center, Rotterdam, NetherlandsDepartment of EndocrinologyI.M. Sechenov First Moscow State Medical University, Moscow, Russian FederationDepartment of EndocrinologyPauls Stradins Clinical University Hospital, Riga, LatviaDivision of Endocrinology and MetabolismSamsung Medical Center, Sungkyunkwan University, Seoul, Republic of KoreaDepartment of Neuroendocrinology and Bone DiseasesNational Endocrinology Research Centre, Moscow, Russian FederationNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, BrazilEndocrine SectionHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilIpsen Boulogne-BillancourtFrance.
Liudmila RozhinskayaDepartment of EndocrinologyErasmus Medical Center, Rotterdam, NetherlandsDepartment of EndocrinologyI.M. Sechenov First Moscow State Medical University, Moscow, Russian FederationDepartment of EndocrinologyPauls Stradins Clinical University Hospital, Riga, LatviaDivision of Endocrinology and MetabolismSamsung Medical Center, Sungkyunkwan University, Seoul, Republic of KoreaDepartment of Neuroendocrinology and Bone DiseasesNational Endocrinology Research Centre, Moscow, Russian FederationNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, BrazilEndocrine SectionHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilIpsen Boulogne-BillancourtFrance.
Marcello D BronsteinDepartment of EndocrinologyErasmus Medical Center, Rotterdam, NetherlandsDepartment of EndocrinologyI.M. Sechenov First Moscow State Medical University, Moscow, Russian FederationDepartment of EndocrinologyPauls Stradins Clinical University Hospital, Riga, LatviaDivision of Endocrinology and MetabolismSamsung Medical Center, Sungkyunkwan University, Seoul, Republic of KoreaDepartment of Neuroendocrinology and Bone DiseasesNational Endocrinology Research Centre, Moscow, Russian FederationNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, BrazilEndocrine SectionHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilIpsen Boulogne-BillancourtFrance.
Mônica R GadelhaDepartment of EndocrinologyErasmus Medical Center, Rotterdam, NetherlandsDepartment of EndocrinologyI.M. Sechenov First Moscow State Medical University, Moscow, Russian FederationDepartment of EndocrinologyPauls Stradins Clinical University Hospital, Riga, LatviaDivision of Endocrinology and MetabolismSamsung Medical Center, Sungkyunkwan University, Seoul, Republic of KoreaDepartment of Neuroendocrinology and Bone DiseasesNational Endocrinology Research Centre, Moscow, Russian FederationNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, BrazilEndocrine SectionHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilIpsen Boulogne-BillancourtFrance.
Pascal MaisonobeDepartment of EndocrinologyErasmus Medical Center, Rotterdam, NetherlandsDepartment of EndocrinologyI.M. Sechenov First Moscow State Medical University, Moscow, Russian FederationDepartment of EndocrinologyPauls Stradins Clinical University Hospital, Riga, LatviaDivision of Endocrinology and MetabolismSamsung Medical Center, Sungkyunkwan University, Seoul, Republic of KoreaDepartment of Neuroendocrinology and Bone DiseasesNational Endocrinology Research Centre, Moscow, Russian FederationNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, BrazilEndocrine SectionHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilIpsen Boulogne-BillancourtFrance.
Caroline SertDepartment of EndocrinologyErasmus Medical Center, Rotterdam, NetherlandsDepartment of EndocrinologyI.M. Sechenov First Moscow State Medical University, Moscow, Russian FederationDepartment of EndocrinologyPauls Stradins Clinical University Hospital, Riga, LatviaDivision of Endocrinology and MetabolismSamsung Medical Center, Sungkyunkwan University, Seoul, Republic of KoreaDepartment of Neuroendocrinology and Bone DiseasesNational Endocrinology Research Centre, Moscow, Russian FederationNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, BrazilEndocrine SectionHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilIpsen Boulogne-BillancourtFrance.
Aart Jan van der LelyDepartment of EndocrinologyErasmus Medical Center, Rotterdam, NetherlandsDepartment of EndocrinologyI.M. Sechenov First Moscow State Medical University, Moscow, Russian FederationDepartment of EndocrinologyPauls Stradins Clinical University Hospital, Riga, LatviaDivision of Endocrinology and MetabolismSamsung Medical Center, Sungkyunkwan University, Seoul, Republic of KoreaDepartment of Neuroendocrinology and Bone DiseasesNational Endocrinology Research Centre, Moscow, Russian FederationNeuroendocrine UnitDivision of Endocrinology and Metabolism, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, BrazilEndocrine SectionHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, BrazilIpsen Boulogne-BillancourtFrance.
LEAD Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate extended dosing intervals (EDIs) with lanreotide Autogel 120 mg in patients with acromegaly previously biochemically controlled with octreotide LAR 10 or 20 mg. DESIGN AND

methodsPatients with acromegaly had received octreotide LAR 10 or 20 mg/4 weeks for ≥ 6 months and had normal IGF1 levels. Lanreotide Autogel 120 mg was administered every 6 weeks for 24 weeks (phase 1); depending on week-24 IGF1 levels, treatment was then administered every 4, 6 or 8 weeks for a further 24 weeks (phase 2). Hormone levels, patient-reported outcomes and adverse events were assessed. PRIMARY ENDPOINT: proportion of patients on 6- or 8-week EDIs with normal IGF1 levels at week 48 (study end).

results107/124 patients completed the study (15 withdrew from phase 1 and two from phase 2). Of 124 patients enrolled, 77.4% were allocated to 6- or 8-week EDIs in phase 2 and 75.8% (95% CI: 68.3-83.3) had normal IGF1 levels at week 48 with the EDI (primary analysis). A total of 88.7% (83.1-94.3) had normal IGF1 levels after 24 weeks with 6-weekly dosing. GH levels were ≤ 2.5 μg/l in > 90% of patients after 24 and 48 weeks. Patient preferences for lanreotide Autogel 120 mg every 4, 6 or 8 weeks over octreotide LAR every 4 weeks were high.

conclusionsPatients with acromegaly achieving biochemical control with octreotide LAR 10 or 20 mg/4 weeks are possible candidates for lanreotide Autogel 120 mg EDIs. EDIs are effective and well received among such patients.

Indexed as

AcromegalyAdenomaAdultAgedAntineoplastic AgentsDelayed-Action PreparationsFemaleGrowth Hormone-Secreting Pituitary AdenomaHuman Growth HormoneHumansInsulin-Like Growth Factor IMaleMiddle AgedOctreotidePeptides, CyclicSomatostatinAntineoplastic AgentsDelayed-Action PreparationsHuman Growth HormoneIGF1 protein, humanInsulin-Like Growth Factor IlanreotideOctreotidePeptides, CyclicSomatostatin

Identifiers

PMID26047625
PMCPMC4544680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.